Merck KGaA and Pfizer have entered into a global agreement to co-develop and commercialize Merck’s MSB0010718C, an investigational anti-PD-L1 antibody currently in development as a potential immuno-oncology treatment for multiple tumor types.   The asset will be developed as a single agent and in various combinations with Pfizer and Merck’s portfolio of approved and investigational pipeline candidates. The two companies will also combine resources and expertise to advance Pfizer’s anti-PD-1 anti...